Synonyms: caprylic triglyceride, long-chain triglyceride
Therapy Type: Dietary Supplement
Target Type: Other
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Phase 3)
Company: Accera, Inc.
Approved for: None
AC-1204 is designed to induce chronic ketosis in order to improve mitochondrial metabolism. An early and prominent feature of Alzheimer's disease is regional cerebral hypometabolism (Reiman et al., 2004). Therapies aimed at correcting cellular metabolism may be beneficial. Endogenous ketone bodies, such as acetoacetic acid, and beta-hydroxybutyric acid, can be converted to acetyl-CoA to produce energy, via the citric acid cycle.
Clinical Trial Timeline
- Phase 2/3
- Study completed / Planned end date
- Planned end date unavailable
- Study aborted
No Available References
No Available Further Reading